{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:00:27Z","timestamp":1777633227770,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.medmal.2017.07.002","type":"journal-article","created":{"date-parts":[[2017,8,16]],"date-time":"2017-08-16T09:45:34Z","timestamp":1502876734000},"page":"532-539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable?"],"prefix":"10.1016","volume":"47","author":[{"given":"C.","family":"Robin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"H\u00e9quette-Ruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Guery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Herbaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Galperine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2017.07.002_bib0205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jhin.2014.08.008","article-title":"Excess length of stay and mortality due to Clostridium difficile infection: a multi-state modelling approach","volume":"88","author":"van Kleef","year":"2014","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.medmal.2017.07.002_bib0210","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cmi.2014.08.017","article-title":"Recurrent Clostridium difficile infection is associated with increased mortality","volume":"21","author":"Olsen","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medmal.2017.07.002_bib0215","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ajg.2015.48","article-title":"The economic impact of Clostridium difficile infection: a systematic review","volume":"110","author":"Nanwa","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medmal.2017.07.002_bib0220","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jhin.2015.06.017","article-title":"Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals","volume":"91","author":"Le Monnier","year":"2015","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.medmal.2017.07.002_bib0225","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2017.07.002_bib0230","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1017\/ice.2015.138","article-title":"Clostridium difficile infection among veterans health administration patients","volume":"36","author":"Young-Xu","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.medmal.2017.07.002_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157489110790112608","article-title":"Clostridium difficile infection following chemotherapy","volume":"5","author":"Raza","year":"2010","journal-title":"Recent Patents Anti-Infect Drug Disc"},{"key":"10.1016\/j.medmal.2017.07.002_bib0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/157489112801619674","article-title":"The evolution of Clostridium difficile infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management","volume":"7","author":"Khan","year":"2012","journal-title":"Recent Patents Anti-Infect Drug Disc"},{"key":"10.1016\/j.medmal.2017.07.002_bib0245","first-page":"3103","article-title":"Excess risk of Clostridium difficile infection in ovarian cancer is related to exposure to broad-spectrum antibiotics","volume":"21","author":"Kim","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.medmal.2017.07.002_bib0250","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1056\/NEJMra0707500","article-title":"Clostridium difficile\u00a0\u2013\u00a0more difficult than ever","volume":"359","author":"Kelly","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2017.07.002_bib0255","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2012.45.5899","article-title":"Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin","volume":"31","author":"Cornely","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medmal.2017.07.002_bib0260","doi-asserted-by":"crossref","first-page":"e28654","DOI":"10.1371\/journal.pone.0028654","article-title":"Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting","volume":"6","author":"Zwielehner","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.medmal.2017.07.002_bib0265","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.bbmt.2014.06.001","article-title":"Clostridium difficile infection in the hematopoietic unit: a meta-analysis of published studies","volume":"20","author":"Zacharioudakis","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.medmal.2017.07.002_bib0270","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s12185-014-1577-z","article-title":"Incidence and outcomes of Clostridium difficile-associated disease in hematopoietic cell transplant recipients","volume":"99","author":"Guddati","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.medmal.2017.07.002_bib0275","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/cid\/cir1035","article-title":"Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients","volume":"54","author":"Alonso","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2017.07.002_bib0280","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.bbmt.2014.06.025","article-title":"Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1\/027","volume":"20","author":"Kamboj","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.medmal.2017.07.002_bib0285","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.bbmt.2014.02.022","article-title":"Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis","volume":"20","author":"Vehreschild","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.medmal.2017.07.002_bib0290","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"Suppl. 2","key":"10.1016\/j.medmal.2017.07.002_bib0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12418","article-title":"European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection","volume":"20","author":"Debast","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medmal.2017.07.002_bib0300","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ajg.2013.4","article-title":"Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections","volume":"108","author":"Surawicz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medmal.2017.07.002_bib0305","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medmal.2017.07.002_bib0310","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2017.07.002_bib0315","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent Clostridium difficile","volume":"368","author":"van Nood","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2017.07.002_bib0320","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1086\/669081","article-title":"Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy","volume":"34","author":"Wang","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.medmal.2017.07.002_bib0325","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.anaerobe.2015.08.002","article-title":"Factors predictive of severe Clostridium difficile infection depend on the definition used","volume":"37","author":"Khanafer","year":"2016","journal-title":"Anaerobe"},{"key":"10.1016\/j.medmal.2017.07.002_bib0330","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/MCG.0000000000000046","article-title":"Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review","volume":"48","author":"Cammarota","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.medmal.2017.07.002_bib0335","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ajg.2013.59","article-title":"Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis","volume":"108","author":"Kassam","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medmal.2017.07.002_bib0340","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/1078155213490004","article-title":"A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies","volume":"20","author":"Parmar","year":"2014","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.medmal.2017.07.002_bib0345","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/AAC.01120-13","article-title":"Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea","volume":"57","author":"Clutter","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2017.07.002_bib0350","first-page":"2015","article-title":"Metronidazole-induced encephalopathy after prolonged metronidazole course for treatment of C.\u00a0difficile colitis","author":"Godfrey","year":"2015","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.medmal.2017.07.002_bib0355","doi-asserted-by":"crossref","first-page":"e98400","DOI":"10.1371\/journal.pone.0098400","article-title":"Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review","volume":"9","author":"Abou Chakra","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.medmal.2017.07.002_bib0360","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/cid\/ciu107","article-title":"Risk estimation for recurrent Clostridium difficile infection based on clinical factors","volume":"58","author":"D\u2019Agostino","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2017.07.002_bib0365","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1017\/ice.2014.88","article-title":"Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis","volume":"36","author":"Deshpande","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.medmal.2017.07.002_bib0370","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/phar.1479","article-title":"The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer","volume":"34","author":"Esmaily-Fard","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.medmal.2017.07.002_bib0375","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/bmt.2014.212","article-title":"Fecal microbiota transplant after hematopoietic SCT: report of a successful case","volume":"50","author":"de Castro","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.medmal.2017.07.002_bib0380","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ajt.12577","article-title":"Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients","volume":"14","author":"Friedman-Moraco","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.medmal.2017.07.002_bib0385","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/ajg.2014.133","article-title":"Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients","volume":"109","author":"Kelly","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medmal.2017.07.002_bib0390","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/jamainternmed.2015.4114","article-title":"Overdiagnosis of Clostridium difficile infection in the Molecular Test Era","volume":"175","author":"Polage","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.medmal.2017.07.002_bib0395","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/676433","article-title":"Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C.\u00a0difficile-associated disease rates","volume":"35","author":"Koo","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.medmal.2017.07.002_bib0400","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.bmt.1702484","article-title":"Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients","volume":"26","author":"van Kraaij","year":"2000","journal-title":"Bone Marrow Transplant"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X1630779X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X1630779X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:15:46Z","timestamp":1759972546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X1630779X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0399077X1630779X"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2017.07.002","relation":{},"ISSN":["0399-077X"],"issn-type":[{"value":"0399-077X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable?","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2017.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}